ijcr@oajrc.org

国际临床研究杂志

International Journal of Clinical Research

您当前位置:首页 > 精选文章

International Journal of Clinical Research. 2024; 8: (1) ; 10.12208/j.ijcr.20240031 .

Clinical efficacy of tirofiban combined with dual antibodies in the treatment of progressive stroke
替罗非班联合双抗治疗进展性脑卒中的临床效果

作者: 张国威 *

惠东县人民医院 广东惠州

*通讯作者: 张国威,单位:惠东县人民医院 广东惠州;

引用本文: 张国威 替罗非班联合双抗治疗进展性脑卒中的临床效果[J]. 国际临床研究杂志, 2024; 8: (1) : 115-117.
Published: 2024/1/20 14:20:16

摘要

目的 开展替罗非班联合双抗治疗方案对进展性脑卒中患者的影响探析。方法 以2023年1月-12月时间段中于院内接受诊疗的进展性脑卒中患者为分析对象,共计95例,按照诊疗先后顺序设置成对照组(49例)、观察组(46例),两组分别行常规手段、替罗非班联合双抗治疗手段,对干预情况进行分析。结果 炎症指标及凝血指标方面,两组相比,治疗后观察组各项值更低(P<0.05)。FIM评分、MoCA评分、MMSE评分、Barthel指数等方面,两组相比,治疗后观察组各项值更高(P<0.05)。结论 在临床中实施替罗非班联合双抗治疗方案,能够对进展性脑卒中患者产生积极影响。

关键词: 进展性脑卒中;替罗非班;双抗治疗

Abstract

Objective To explore the effect of Tirofiban combined with double antibody therapy on patients with progressive stroke.
Methods A total of 95 patients with progressive stroke who received diagnosis and treatment in hospital from January to December 2023 were selected as the analysis objects, and they were divided into control group (49 cases) and observation group (46 cases) according to the order of diagnosis and treatment. The two groups were respectively treated with conventional means and Tirofiban combined with double antibody treatment, and the intervention situation was analyzed.
Results The inflammation index and coagulation index of the two groups were lower than that of the observation group after treatment (P<0.05). FIM score, MoCA score, MMSE score and Barthel index were higher in the observation group after treatment than in the two groups (P<0.05).
Conclusion   The clinical implementation of Tirofiban combined with double antibody therapy can have a positive effect on patients with progressive stroke.

Key words: Progressive stroke; Tirofiban; Double antibody therapy

参考文献 References

[1] 孟庆伟,李莉. 替罗非班与双抗治疗进展性脑卒中的疗效对比[J]. 中国继续医学教育,2020,12(30):138-141. 

[2] 张清秀,付家亮,荣良群,等. 基于脑卒中注册的双抗治疗进展性脑卒中的疗效[J]. 中国老年学杂志,2019,39(11): 2602-2604. 

[3] 高艳,李文东. 替罗非班辅助治疗进展性脑卒中的效果分析及对患者凝血功能相关指标的影响[J]. 智慧健康,2022,8(11):117-120. 

[4] 韩芳,任杰,常伟东. 替罗非班辅助双抗血小板治疗进展性脑卒中的疗效分析[J]. 癫痫与神经电生理学杂志,2021,30(6):355-358.

[5] 董春蕊,张广玉. 应用替罗非班治疗前循环进展性卒中的疗效及安全性分析[J]. 医学美学美容,2020,29(20):3-5.

[6] 崔凡凡,靳奥洁,李艳玲,等. 替罗非班联合双抗治疗进展性脑卒中的疗效观察[J]. 中国现代医学杂志,2019, 29(16):69-74. 

[7] 张丽荣. 替罗非班与双抗治疗进展性脑卒中的疗效与安全性对比[J]. 中国民康医学,2019,31(14):7-9. 

[8] 孙海滨,包华. 双抗治疗进展性脑卒中的效果观察[J]. 中国现代医生,2021,59(36):57-59,63.

[9] 韦恒宇,黄丹丹,邱观养. 替罗非班联合双抗治疗进展性脑卒中的临床效果[J]. 智慧健康,2020,6(32):98-100.

[10] 马嘉琦,李映辰,伍大华. 替罗非班联合双抗治疗进展性脑卒中有效性及安全性的Meta分析[J]. 中国神经免疫学和神经病学杂志,2023,30(5):342-348,367.